RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated his 'Outperform' rating on BioCryst Pharma (NASDAQ:BCRX), maintaining a price target of $10.
September 25, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital's reiteration of an 'Outperform' rating and a $10 price target for BioCryst Pharma could potentially boost investor confidence.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of an 'Outperform' rating and a $10 price target by RBC Capital indicates their continued confidence in BioCryst Pharma, which could potentially boost the stock's performance in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100